logo-loader
viewLexagene Holdings Inc.

Full interview: Lexagene makes key hire as they hope to have their LX Analyzer to market in Q-3

Lexagene (CVE: LXG- OTCQB: LXXGF) Co-Founder and CEO Dr Jack Regan joined Steve Darling from Proactive Vancouver to discuss the hiring of Steven Armstrong as the company’s Senior Director of Operations. Regan explains the skills he is bringing to the job.

Regan also told Proactive the latest on manufacturing its flagship LX Genetic Analyzer for rapid pathogen detection. Lexagene recently revealed that it is accelerating the submission of its LX Analyzer to the FDA as the COVID-19 outbreak expands.

Quick facts: Lexagene Holdings Inc.

Price: 0.86 CAD

TSX-V:LXG
Market: TSX-V
Market Cap: $77 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Lexagene Holdings Inc. named herein, including the promotion by the Company of Lexagene Holdings Inc. in any Content on the Site, the Company...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: LexaGene hits milestone by having pre-commercial device in...

LexaGene (CVE: LXG- OTCQB: LXXGF) CEO Dr Jack Regan joined Steve Darling from Proactive Vancouver with news the company now has one of their devices that tests for COVID-19 and other respiratory pathogens being used at the Dartmouth-Hitchcock Medical Center in Hanover, New Hampshire. Regan...

on 28/5/20

2 min read